Viking Therapeutics, Inc. Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Viking Therapeutics, Inc. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2025-12-31 was $1.16M, a 15.50% increase year-over-year.
- Viking Therapeutics, Inc. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2025-09-30 was $480.00K, a 80.97% decline year-over-year.
- Viking Therapeutics, Inc. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2025-06-30 was $507.00K, a 82.70% decline year-over-year.
- Viking Therapeutics, Inc. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2024-12-31 was $1.00M, a 431.91% increase year-over-year.
- Viking Therapeutics, Inc. shares issued, value, share-based payment arrangement, before forfeiture for fiscal 2025 was $2.49M, a 76.96% decline from fiscal 2024.
- Viking Therapeutics, Inc. shares issued, value, share-based payment arrangement, before forfeiture for fiscal 2024 was $10.81M, a 59.77% increase from fiscal 2023.
- Viking Therapeutics, Inc. shares issued, value, share-based payment arrangement, before forfeiture for fiscal 2023 was $6.77M, a 3047.91% increase from fiscal 2022.
- Viking Therapeutics, Inc. shares issued, value, share-based payment arrangement, before forfeiture for fiscal 2022 was $215.00K, a 62.28% decline from fiscal 2021.
| Period end | Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture 3 month | Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture 12 month |
|---|---|---|
| 2025-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $2.49M 10-K · filed 2026-02-11 |
| 2025-09-30 | $480.00K 10-Q · filed 2025-10-23 | |
| 2025-06-30 | $507.00K 10-Q · filed 2026-07-29 | |
| 2024-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $10.81M 10-K · filed 2026-02-11 |
| 2024-09-30 | $2.52M 10-Q · filed 2025-10-23 | $10.00M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $2.93M 10-Q · filed 2025-07-23 | $7.48M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | $4.36M 10-Q · filed 2025-04-24 | $7.16M derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | $188.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $6.77M 10-K · filed 2026-02-11 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-23 | $6.71M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $2.62M 10-Q · filed 2024-07-24 | $6.71M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $3.97M 10-Q · filed 2024-04-25 | $4.18M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $131.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $215.00K 10-K · filed 2025-02-26 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-25 | |
| 2022-06-30 | $84.00K 10-Q · filed 2023-07-26 | |
| 2021-12-31 | $66.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-07 | $570.00K 10-K · filed 2024-02-07 |
| 2021-09-30 | $6.00K 10-Q · filed 2022-10-26 | $579.00K derived: sum of 4 quarters · filed 2022-10-26 |
| 2021-06-30 | $343.00K 10-Q · filed 2022-07-27 | $678.00K derived: sum of 4 quarters · filed 2022-07-27 |
| 2021-03-31 | $156.00K 10-Q · filed 2022-04-27 | $562.00K derived: sum of 4 quarters · filed 2022-04-27 |
| 2020-12-31 | $74.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $418.00K 10-K · filed 2022-02-09 |
| 2020-09-30 | $105.00K 10-Q · filed 2021-11-03 | $410.00K derived: sum of 4 quarters · filed 2021-11-03 |
| 2020-06-30 | $227.00K 10-Q · filed 2021-07-28 | $395.00K derived: sum of 4 quarters · filed 2021-07-28 |
| 2020-03-31 | $12.00K 10-Q · filed 2021-04-28 | $275.00K derived: sum of 4 quarters · filed 2021-04-28 |
| 2019-12-31 | $66.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17 | $328.00K 10-K · filed 2021-02-17 |
| 2019-09-30 | $90.00K 10-Q · filed 2020-10-28 | $352.00K derived: sum of 4 quarters · filed 2020-10-28 |
| 2019-06-30 | $107.00K 10-Q · filed 2020-07-29 | $419.00K derived: sum of 4 quarters · filed 2020-07-29 |
| 2019-03-31 | $65.00K 10-Q · filed 2020-04-30 | $554.00K derived: sum of 4 quarters · filed 2020-04-30 |
| 2018-12-31 | $90.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $560.00K 10-K · filed 2020-02-26 |
| 2018-09-30 | $157.00K 10-Q · filed 2019-11-05 | $525.00K derived: sum of 4 quarters · filed 2019-11-05 |
| 2018-06-30 | $242.00K 10-Q · filed 2019-08-01 | |
| 2018-03-31 | $73.00K 10-Q · filed 2019-05-02 | |
| 2017-12-31 | $53.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $73.00K 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |